Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
PCRX•Viatris will buy Pacira BioSciences for $1.65 billion in cash, or $36.50 per share, a premium of about 44.8% to Pacira’s last close. The companies expect the deal to close by the end of 2026.
1. Deal terms
Viatris agreed to buy Pacira BioSciences for $1.65 billion in cash, paying $36.50 per share. The offer adds Pacira’s non-opioid pain drugs Exparel and Zilretta to Viatris’ portfolio; the companies expect the deal to close by the end of 2026.
